Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome

Gianpaolo Nadali, Luisa Tavecchia, Elisabetta Zanolin, Valeria Bonfante, Simonetta Viviani, Edgarda Camerini, Pellegrino Musto, Nicola Di Renzo, Mario Carotenuto, Marco Chilosi, Mauro Krampera, Giovanni Pizzolo

Research output: Contribution to journalArticle

Abstract

Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration of diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years of patients with sCD30 levels ≤ 100 and less than 100 U/mL was 59.9% (95% confidence interval [CI], 40.6% to 65.9%) and 87.5% (95% CI, 81.5% to 91.6%), respectively (P <.001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≤50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≤100 U/mL: EFS, 46.9%) and low risk (stages I and II with sCD30 <100 U/mL: EFS, 88.7%) of treatment failure (P <.001). We conclude that the combined evaluation of sCD30 serum level and stage at presentation identifies patients with HD at high risk of an unfavorable outcome.

Original languageEnglish
Pages (from-to)3011-3016
Number of pages6
JournalBlood
Volume91
Issue number8
Publication statusPublished - Apr 15 1998

Fingerprint

Hodgkin Disease
Molecules
Disease-Free Survival
Serum
Confidence Intervals
Tumors
Hemoglobins
Tumor Burden
Treatment Failure

ASJC Scopus subject areas

  • Hematology

Cite this

Nadali, G., Tavecchia, L., Zanolin, E., Bonfante, V., Viviani, S., Camerini, E., ... Pizzolo, G. (1998). Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood, 91(8), 3011-3016.

Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. / Nadali, Gianpaolo; Tavecchia, Luisa; Zanolin, Elisabetta; Bonfante, Valeria; Viviani, Simonetta; Camerini, Edgarda; Musto, Pellegrino; Di Renzo, Nicola; Carotenuto, Mario; Chilosi, Marco; Krampera, Mauro; Pizzolo, Giovanni.

In: Blood, Vol. 91, No. 8, 15.04.1998, p. 3011-3016.

Research output: Contribution to journalArticle

Nadali, G, Tavecchia, L, Zanolin, E, Bonfante, V, Viviani, S, Camerini, E, Musto, P, Di Renzo, N, Carotenuto, M, Chilosi, M, Krampera, M & Pizzolo, G 1998, 'Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome', Blood, vol. 91, no. 8, pp. 3011-3016.
Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 1998 Apr 15;91(8):3011-3016.
Nadali, Gianpaolo ; Tavecchia, Luisa ; Zanolin, Elisabetta ; Bonfante, Valeria ; Viviani, Simonetta ; Camerini, Edgarda ; Musto, Pellegrino ; Di Renzo, Nicola ; Carotenuto, Mario ; Chilosi, Marco ; Krampera, Mauro ; Pizzolo, Giovanni. / Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. In: Blood. 1998 ; Vol. 91, No. 8. pp. 3011-3016.
@article{fddbacf0604c425eaa1ce5a3a38429f1,
title = "Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome",
abstract = "Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration of diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years of patients with sCD30 levels ≤ 100 and less than 100 U/mL was 59.9{\%} (95{\%} confidence interval [CI], 40.6{\%} to 65.9{\%}) and 87.5{\%} (95{\%} CI, 81.5{\%} to 91.6{\%}), respectively (P <.001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≤50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≤100 U/mL: EFS, 46.9{\%}) and low risk (stages I and II with sCD30 <100 U/mL: EFS, 88.7{\%}) of treatment failure (P <.001). We conclude that the combined evaluation of sCD30 serum level and stage at presentation identifies patients with HD at high risk of an unfavorable outcome.",
author = "Gianpaolo Nadali and Luisa Tavecchia and Elisabetta Zanolin and Valeria Bonfante and Simonetta Viviani and Edgarda Camerini and Pellegrino Musto and {Di Renzo}, Nicola and Mario Carotenuto and Marco Chilosi and Mauro Krampera and Giovanni Pizzolo",
year = "1998",
month = "4",
day = "15",
language = "English",
volume = "91",
pages = "3011--3016",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome

AU - Nadali, Gianpaolo

AU - Tavecchia, Luisa

AU - Zanolin, Elisabetta

AU - Bonfante, Valeria

AU - Viviani, Simonetta

AU - Camerini, Edgarda

AU - Musto, Pellegrino

AU - Di Renzo, Nicola

AU - Carotenuto, Mario

AU - Chilosi, Marco

AU - Krampera, Mauro

AU - Pizzolo, Giovanni

PY - 1998/4/15

Y1 - 1998/4/15

N2 - Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration of diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years of patients with sCD30 levels ≤ 100 and less than 100 U/mL was 59.9% (95% confidence interval [CI], 40.6% to 65.9%) and 87.5% (95% CI, 81.5% to 91.6%), respectively (P <.001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≤50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≤100 U/mL: EFS, 46.9%) and low risk (stages I and II with sCD30 <100 U/mL: EFS, 88.7%) of treatment failure (P <.001). We conclude that the combined evaluation of sCD30 serum level and stage at presentation identifies patients with HD at high risk of an unfavorable outcome.

AB - Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin's disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration of diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years of patients with sCD30 levels ≤ 100 and less than 100 U/mL was 59.9% (95% confidence interval [CI], 40.6% to 65.9%) and 87.5% (95% CI, 81.5% to 91.6%), respectively (P <.001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≤50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≤100 U/mL: EFS, 46.9%) and low risk (stages I and II with sCD30 <100 U/mL: EFS, 88.7%) of treatment failure (P <.001). We conclude that the combined evaluation of sCD30 serum level and stage at presentation identifies patients with HD at high risk of an unfavorable outcome.

UR - http://www.scopus.com/inward/record.url?scp=0032523174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032523174&partnerID=8YFLogxK

M3 - Article

C2 - 9531614

AN - SCOPUS:0032523174

VL - 91

SP - 3011

EP - 3016

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -